CLINICAL TRIALS PROFILE FOR TOLCAPONE
✉ Email this page to a colleague
All Clinical Trials for tolcapone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00033059 ↗ | Assessment of Potential Interactions Between Cocaine and Tolcapone - 1 | Unknown status | National Institute on Drug Abuse (NIDA) | Phase 1 | 2001-07-01 | The purpose of this study is to assess the potential interactions between intravenous (IV) cocaine and tolcapone. |
NCT00044083 ↗ | Clinical Trial of Tolcapone for Cognition in Schizophrenia | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2002-08-01 | This study will evaluate whether Tolcapone improves cognition in healthy volunteers as well as patients with schizophrenia. Talcapone is a drug that has been FDA approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. ... |
NCT00548327 ↗ | The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype | Terminated | National Institute of Mental Health (NIMH) | Phase 2 | 2007-10-01 | This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tolcapone
Condition Name
Clinical Trial Locations for tolcapone
Trials by Country
Clinical Trial Progress for tolcapone
Clinical Trial Phase
Clinical Trial Sponsors for tolcapone
Sponsor Name